INSEEGO CORP. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that INSEEGO CORP. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $86.06M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $90.24M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $80.69M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $56.84M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $52.33M | Mar 1, 2021 |
| FY2020 | Sep 30, 2019 | $62.72M | Mar 1, 2021 |
| FY2020 | Jun 30, 2019 | $55.89M | Mar 1, 2021 |
| FY2020 | Mar 31, 2019 | $48.56M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $56.04M | Mar 16, 2020 |
| FY2019 | Sep 30, 2018 | $50.63M | Mar 16, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $166.19M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $191.24M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $167.29M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $245.32M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $262.40M | Mar 3, 2023 |
| FY2022 | Dec 31, 2020 | $313.83M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $219.50M | Mar 1, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $68.80M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $35.78M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $66.91M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $75.93M | Mar 3, 2023 |
| FY2020 | Dec 31, 2020 | $26.45M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $25.17M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $22.00M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $17.23M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $15.03M | Mar 1, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $838.0K | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $4.57M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | ($46.19M) | Feb 20, 2025 |
| FY2022 | Dec 31, 2022 | ($67.97M) | Mar 3, 2023 |
| FY2022 | Dec 31, 2021 | ($48.13M) | Mar 3, 2023 |
| FY2022 | Dec 31, 2020 | ($111.22M) | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | ($40.13M) | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | ($8.06M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($45.74M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($60.57M) | Mar 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.32M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.72M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | ($35.96M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($57.92M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($46.52M) | Mar 3, 2023 |
| FY2022 | Dec 31, 2020 | ($25.13M) | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | ($19.54M) | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $14.01M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($22.21M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($45.00M) | Mar 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.80M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $20.60M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $19.73M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $38.29M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $52.67M | Mar 3, 2023 |
| FY2022 | Dec 31, 2020 | $44.95M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $23.85M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $20.59M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $21.36M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $30.66M | Mar 16, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.20M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $33.52M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $5.96M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($33.29M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($25.21M) | Mar 3, 2023 |
| FY2022 | Dec 31, 2020 | $20.05M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | ($18.00M) | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | ($1.77M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($14.58M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($6.58M) | Mar 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $661.0K | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $100.0K | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $224.0K | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.48M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $4.93M | Mar 3, 2023 |
| FY2022 | Dec 31, 2020 | $5.74M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $6.62M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $1.34M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $1.79M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $1.44M | Mar 16, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.81M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $100.00M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $121.80M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $159.95M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $215.84M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $227.39M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $161.37M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $162.26M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $158.21M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $158.72M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.85M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $112.86M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $223.90M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $230.07M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $240.70M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $255.29M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $198.73M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $198.78M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $203.82M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $176.44M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.04M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($12.86M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | ($102.11M) | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | ($70.12M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($24.85M) | Feb 22, 2024 |
| FY2021 | Dec 31, 2020 | ($27.81M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($37.24M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($36.39M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($45.57M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($17.76M) | Mar 16, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.95M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $3.95M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $3.95M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $21.92M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $20.34M | Mar 3, 2023 |
| FY2022 | Dec 31, 2020 | $32.51M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $33.66M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $32.94M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $37.68M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $34.43M | Mar 12, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($908.36M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($905.63M) | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | ($906.93M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($857.75M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($787.05M) | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | ($732.42M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($618.30M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($577.82M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($569.76M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($524.02M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.89M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $39.60M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $2.41M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $7.14M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $46.47M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $40.02M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $12.07M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $31.02M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $21.20M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $9.89M | Mar 16, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $152.63M | Mar 16, 2020 |
| FY2018 | Dec 31, 2018 | $152.63M | Mar 12, 2019 |
| FY2017 | Dec 31, 2017 | $153.46M | Mar 16, 2018 |
| FY2016 | Dec 31, 2016 | $120.59M | Mar 31, 2017 |
| FY2015 | Dec 31, 2015 | $124.06M | Mar 15, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 3, 2023 |
| FY2022 | Dec 31, 2020 | (1) | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | 0 | Mar 16, 2020 |
| FY2019 | Sep 30, 2018 | 0 | Mar 16, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Mar 16, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 3, 2023 |
| FY2022 | Dec 31, 2020 | (1) | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | 0 | Mar 16, 2020 |
| FY2019 | Sep 30, 2018 | 0 | Mar 16, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Mar 16, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15.39M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 14.99M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | 11.88M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 10.85M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 105.38M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | 99.40M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 81.97M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 73.98M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 58.64M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 54.37M | Mar 16, 2018 |